| Filed On | Filing |
|---|---|
| 03 Dec 2024 |
8-K/A: Regulation FD Disclosure; Other Events
TNX - 102 SL Lead Indication : Fibromyalgia Additional Indication: Acute Stress Disorder NASDAQ: TNXP December 2024 © 2024 Tonix Pharmaceuticals Holding Corp. PO6027 December 3, 2024 (Doc 1539) |
| 24 Jul 2024 |
8-K/A: Material Impairments; Shareholder Director Nominations
As previously disclosed in the Current Report on Form 8-K filed by Tonix Pharmaceuticals Holding Corp. (the “Company”) with the Securities Exchange Commission (the “SEC”) on May 22, 2024, the Company announced that it decommissioned its ... |
| 14 Jun 2024 |
8-K/A: Financial Statements and Exhibits
We have acted as counsel to Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”) in connection with the sale and issuance of 1,199,448 shares of the Company’s common stock, par value $0.001 per share (the “Common Sto... |
| 18 Jul 2023 |
8-K/A: Financial Statements and Exhibits
On June 30, 2023 (the “Closing”), pursuant to an Asset Purchase Agreement entered into on June 23, 2023 with Upsher-Smith Laboratories LLC, (“Seller”), Tonix Pharmaceuticals Holding Corp. and its wholly-owned subsidiary, Tonix Medicines,... |
| 29 Jun 2016 | 8-K/A: Regulation FD Disclosure |
| 27 Dec 2012 | 8-K/A: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more |
| 11 May 2012 | 8-K/A: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure |
| 03 Apr 2012 | 8-K/A: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +6 more |
| 03 Feb 2012 | 8-K/A: Financial Statements and Exhibits |
| 27 Dec 2011 | 8-K/A: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +6 more |
Loading...
